Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
4DMedical Ltd ( (AU:4DX) ) has issued an update.
4DMedical Limited has announced a collaboration with AstraZeneca in Brazil and a new contract with Spectrum Medical Imaging, marking its first involvement in Australia’s National Lung Cancer Screening Program. While the Spectrum contract is not immediately significant in terms of revenue, it is expected to grow over time, highlighting 4DMedical’s strategic expansion and potential impact on lung health management.
The most recent analyst rating on (AU:4DX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
More about 4DMedical Ltd
4DMedical Limited is a global medical technology company specializing in advanced respiratory imaging and artificial intelligence. The company offers innovative solutions like the XV Technology® and XV Lung Ventilation Analysis Software, which enhance the detection, diagnosis, and monitoring of lung diseases. 4DMedical’s products are delivered through a Software-as-a-Service model, integrating seamlessly into existing hospital systems to improve physician productivity and patient care. The company’s recent acquisition of Imbio has further advanced its AI capabilities, reinforcing its position as a leader in medical imaging.
Average Trading Volume: 4,649,380
Technical Sentiment Signal: Buy
Current Market Cap: A$766.7M
Find detailed analytics on 4DX stock on TipRanks’ Stock Analysis page.